Lorenzo Falchi, MD

Dr. Lorenzo Falchi presents primary phase 3 EPCORE FL-1 results showing that epcoritamab plus rituximab and lenalidomide significantly improves efficacy outcomes vs rituximab and lenalidomide alone in relapsed/refractory follicular lymphoma.

Dr Falchi discusses why the FDA approval of epcoritamab plus lenalidomide/rituximab is clinically meaningful for relapsed/refractory follicular lymphoma.

Lorenzo Falchi, MD, discusses the significance of the FDA approval of epcoritamab plus rituximab and lenalidomide for relapsed/ refractory follicular lymphoma.

Lorenzo Falchi, MD, expands on efficacy results from arms 6 and 7 of the phase 1b/2 EPCORE NHL-2 trial of epcoritamab in first-line follicular lymphoma.

Lorenzo Falchi, MD, discusses the safety and pharmacodynamics of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma

Lorenzo Falchi, MD, discusses the safety and efficacy of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

Lorenzo Falchi, MD, discusses the long-term outcomes of fixed-duration epcoritamab plus R-CHOP in previously untreated patients with DLBCL.

Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.

Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.

With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.

A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.

Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.

Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.

Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.

Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.

Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.

Lorenzo Falchi, MD, discusses the ongoing EPCORE FL-1 phase 3 trial investigating epcoritamab-rituximab-lenalidomide vs rituximab-lenalidomide in patients with relapsed or refractory follicular lymphoma.

A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.

Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.

A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.

Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.

Lorenzo Falchi, MD, iscusses the use of glofitamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.

Lorenzo Falchi, MD, discusses the updated findings from the phase 1/2 EPCORE NHL-2 trial trial evaluating the subcutaneous administration of epcoritamab with R-CHOP in patients with high-risk diffuse large B-cell lymphoma.